Premium Nahrungsergänzungsmittel | artgerecht

Neuroblastoma – Causes, Symptoms and Treatment

Neuroblastoma is a malignant tumor arising from immature nerve cells of the sympathetic nervous system, most commonly affecting young children and often originating in the adrenal medulla.

Regular tips about health Regular tips about health

Things worth knowing about "Neuroblastoma"

Neuroblastoma is a malignant tumor arising from immature nerve cells of the sympathetic nervous system, most commonly affecting young children and often originating in the adrenal medulla.

What is Neuroblastoma?

Neuroblastoma is a malignant (cancerous) tumor that develops from immature nerve cells of the sympathetic nervous system. It is one of the most common solid extracranial tumors in childhood, accounting for approximately 8–10% of all childhood cancers. The tumor most frequently arises in the adrenal medulla, but it can develop anywhere along the sympathetic nerve chain — including the abdomen, chest, or neck.

Causes and Risk Factors

The exact causes of neuroblastoma are not yet fully understood. In most cases, the disease occurs sporadically, without a family history. In approximately 1–2% of cases, a hereditary form is present, associated with mutations in the ALK gene (Anaplastic Lymphoma Kinase) or the PHOX2B gene.

Genetic predisposition (familial neuroblastoma)
Mutations in the ALK or PHOX2B genes
Amplification of the MYCN oncogene (associated with more aggressive disease)

Symptoms

Symptoms depend on the location of the tumor and its extent of spread. Neuroblastoma is often not detected until it has already metastasized (spread to other parts of the body).

Palpable lump or swelling in the abdomen
Abdominal pain or a sensation of fullness
Bone pain (due to metastases)
High blood pressure and rapid heartbeat (due to catecholamine secretion)
Pallor, fatigue, and weight loss
Periorbital bruising (so-called raccoon eyes) when metastases affect the eye socket
Breathing difficulties with thoracic (chest) tumors

Diagnosis

Diagnosis of neuroblastoma involves a combination of investigative methods:

Imaging Studies

Ultrasound: Initial investigation for a suspected abdominal mass
CT (Computed Tomography) and MRI (Magnetic Resonance Imaging): For precise localization and assessment of extent
MIBG scintigraphy (Meta-Iodobenzylguanidine): A specialized nuclear medicine scan that reliably detects neuroblastoma cells
PET-CT: Used for MIBG-negative tumors

Laboratory Tests

Measurement of catecholamines and their metabolites (vanillylmandelic acid, homovanillic acid) in urine
NSE (Neuron-Specific Enolase) and LDH (Lactate Dehydrogenase) in blood as tumor markers

Tissue Biopsy

A biopsy of the tumor tissue is obtained for definitive diagnosis and tumor typing, including histological (microscopic tissue) examination. MYCN amplification status is also determined, as it has significant implications for treatment and prognosis.

Staging

Neuroblastomas are classified using the international INRG (International Neuroblastoma Risk Group) system into risk categories: very low, low, intermediate, and high. This classification is based on age, tumor stage, MYCN status, histology, and additional molecular markers.

Treatment

Treatment is guided by the patient's risk group and may include the following approaches:

Low-Risk Neuroblastoma

In very young infants with low-risk disease, a watchful waiting approach may be sufficient, as some tumors regress spontaneously. Surgical removal is performed if necessary.

Intermediate Risk

Surgical removal of the tumor (resection)
Moderate chemotherapy

High-Risk Neuroblastoma

Intensive induction chemotherapy to reduce tumor size
Surgical resection of residual tumor
High-dose chemotherapy followed by autologous stem cell transplantation
Radiotherapy to the tumor bed
Immunotherapy with the antibody Dinutuximab (targeting the ganglioside GD2 on neuroblastoma cells)
Isotretinoin (13-cis-retinoic acid) as differentiation therapy

Prognosis

Prognosis depends strongly on the risk group. Children with low-risk neuroblastoma have excellent survival rates of over 90%. In high-risk neuroblastoma, long-term survival rates remain approximately 40–50% despite intensive therapy. Ongoing clinical trials are investigating new approaches such as targeted therapies (ALK inhibitors) and CAR-T cell therapies to further improve outcomes.

References

Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nature Reviews Clinical Oncology, 2014; 11(12): 704–713.
Matthay KK et al. Neuroblastoma. Nature Reviews Disease Primers, 2016; 2: 16078.
Maris JM. Recent advances in neuroblastoma. New England Journal of Medicine, 2010; 362(23): 2202–2211.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category